

[View the web version of this email](#)

Please do not reply to this message via e-mail. This address is automated, unattended, and cannot help with questions or requests.



Dear Contract Pharmacy Third Party Administrator (TPA),

BMS has developed a coordinated, enterprise-wide approach to the company's distribution practices that impacts the 340B program. As reflected in our letter to covered entities, beginning on March 1, 2022, 340B contracts administered by our wholesalers will reflect these changes. In support of a smooth transition, TPAs may be asked to coordinate with 340B covered entities and wholesalers regarding the contract pharmacy designations that covered entities may choose to make. Two additional FAQs to support TPAs during this transition include:

- **Q: What happens if a covered entity elects not to provide the claim information for contract pharmacy orders of Revlimid®, Pomalyst®, and Thalomid® (IMiDs)?**

BMS needs the claim level detail (including the dispense date) to determine whether or not each IMiD contract pharmacy order complies with BMS' updated distribution practices. BMS will decline to distribute orders of 340B priced drugs to covered entity contract pharmacies that elect not to provide the information. This will apply to all IMiD prescriptions filled by these IMiD-designated specialty contract pharmacies during the period in which a covered entity elects not to provide the information. For example, if a covered entity elects not to actively submit this information from March 1, 2022, through March 31, 2022, and then elects to begin submitting it on April 1, 2022, that covered entity is electing to receive 340B prices for its prescriptions with a dispense date on or after April 1, 2022.

- **Q: How can TPAs support covered entities?**

TPAs can assist by coordinating with covered entities to identify the covered entity's applicable non-IMiD-designated contract pharmacy and/or IMiD-designated specialty contract pharmacy, if selected by the entity. The TPA may wish to determine if the entity chooses to submit claim information to BMS for IMiD orders. If a covered entity chooses to submit this information, TPAs can help the entity complete BMS's information submission form and identify only 340B eligible transactions with dispense dates that align with BMS's distribution practices.

Thank you for your assistance in providing support to ensure a smooth implementation of BMS's integrated distribution practices.

Regards,

A handwritten signature in blue ink, appearing to be a stylized 'M' or 'B' followed by a horizontal line.



Steven Pieri
Bristol Myers Squibb
VP | U.S. Pricing, Contracting, Trade and Government Programs
U.S. Commercial
3401 Princeton Pike
Lawrenceville, NJ 08648
United States of America

You can stop future Bristol Myers Squibb email marketing communications by clicking [here](#) or mailing your request to Bristol Myers Squibb, P.O. Box 869, Palatine, IL 60078-0869.



LEGAL NOTICE | PRIVACY POLICY | UNSUBSCRIBE

©2022 Bristol Myers Squibb Company.

[1/22]